Har­bour Bio­Med jumps in­to the crowd­ed PD-1/L1 race, look­ing to take a Chi­nese as­set glob­al as check­point pipeline bulges

Can two Chi­nese biotechs vault a home­grown PD-L1 agent to fron­trun­ner sta­tus in the crowd­ed glob­al check­point race?

Har­bour Bio­Med thinks the an­swer is yes, and it’s will­ing to spend a to­tal of $350 mil­lion to make that a re­al­i­ty.

Pay­ing an un­spec­i­fied up­front to Cheng­du-based Kelun Biotech — with whom it al­ready has an ear­ly-stage col­lab­o­ra­tion — Har­bour grabs ex­clu­sive rights to de­vel­op, man­u­fac­tur­ing and com­mer­cial­ize A167 out­side of greater Chi­na. Har­bour is head­quar­tered in Shang­hai with a Boston out­post.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.